---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-098369"
form_type: "8-K"
ticker: "GRDX"
cik: "0001604191"
company_name: "GridAI Technologies Corp."
filed_at: "2024-09-10T23:59:59+00:00"
generated_at: "2026-05-31T05:39:17.500331+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Entero Therapeutics signs LOI to license clinical trial compliance platform from DataVault Holdings

## Summary
- Binding LOI for exclusive worldwide license to QOLPOM and FotoDigm clinical trial software from DataVault Holdings.
- Consideration: $250,000 in convertible preferred shares priced at 180% of 5-day VWAP plus single-digit royalties on net sales.
- Deal contingent on Entero securing at least $500,000 strategic investment; target up to $3M.
- License intended to support Entero's planned Phase 3 latiglutenase trial for celiac disease and other GI indications.
- Right of first refusal to fully acquire the assets; closing targeted by end of September 2024.

## SEC filing metadata
- accession: 0001104659-24-098369
- form_type: 8-K
- ticker: GRDX
- cik: 0001604191
- company_name: GridAI Technologies Corp.
- filed_at: 2024-09-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604191/000110465924098369/0001104659-24-098369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604191/000110465924098369/tm2423688d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-098369
- JSON: https://secwatch.observer/filing/0001104659-24-098369.json
- Plain text: https://secwatch.observer/filing/0001104659-24-098369.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.